Merck Hikes Diabetes Exposure Via Acquisition (MRK, JNJ, DEPO, ARRY, MNKD, SPEX, BIOD, AMLN, GNBT, ALKS, LLY, ARNA)
Posted by Jason Smith at 11:39AM on December 2nd
Pharmaceutical giant Merck (MRK) agreed to purchase Beverly, Massachusetts-based insulin maker SmartCells for as much as $500 million, boosting the firm’s exposure the diabetes segment, which generated $2.58 billion in 2009 revenue. Miller Tabak portfolio manager Les Funtleyder told Bloomberg, “We…
Posted by Jason Smith at 1:35PM on March 23rd
Shares of Valencia, California-based Mannkind Corp (MNKD) are rebounding sharply after two days of declines in a recent downtrend spurred by the FDA’s request for additional information related to the company’s Afrezza inhaled insulin. The stock remains off by -10% over…
Posted by Owen Vater at 12:48PM on March 1st
OSI Pharmaceuticals (OSIP) soared by over 50% on Monday after receiving an unsolicited buyout bid from Astellas Pharma (OTC: ALPMY) worth $52 per share.
According to a press release this morning, OSI Pharmaceuticals isn’t interested in the $52 per share offer it received…
Posted by Jason Smith at 12:03PM on February 3rd
Home Diagnositics (HDIX) is soaring today after the company announced a definitive merger agreement with Nipro Corporation. Nipro will pay $11.50 in cash per Home Diagnostics share or $215 million for the company in a two-step acquisition, which is set to…
Posted by Max Magee at 10:04AM on December 15th
Shares of Array BioPharma (ARRY) surged on Tuesday after the small-cap company signed a $60 million deal.
Array BioPharma announced this morning that it has entered an agreement with pharmaceutical giant Amgen (NASDASQ: AMGN). Amgen will pay $60 million upfront and additional milestone…
|Home | Find | Research | Track | Register | My Account | Logout||Web site design by LightMix|
|© 2007-2013 Indie research Corp. All rights reserved.|